PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8+ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients. Academic Article uri icon

Overview

abstract

  • Tumor-reactive T cell exhaustion prevents the success of immune therapies. Pegilodecakin activates intratumoral CD8+ T cells in mice and induces objective tumor responses in patients. Here we report that pegilodecakin induces hallmarks of CD8+ T cell immunity in cancer patients, including elevation of interferon-γ and GranzymeB, expansion and activation of intratumoral CD8+ T cells, and proliferation and expansion of LAG-3+ PD-1+ CD8+ T cells. On pegilodecakin, newly expanded T cell clones, undetectable at baseline, become 1%-10% of the total T cell repertoire in the blood. Elevation of interleukin-18, expansion of LAG-3+ PD-1+ T cells and novel T cell clones each correlated with objective tumor responses. Combined pegilodecakin with anti-PD-1 increased the expansion of LAG-3+ PD-1+ CD8+ T cells.

publication date

  • November 12, 2018

Research

keywords

  • Antineoplastic Agents
  • CD8-Positive T-Lymphocytes
  • Immunotherapy
  • Interleukin-10
  • Lymphocyte Activation
  • Lymphocytes, Tumor-Infiltrating
  • Neoplasms
  • Polyethylene Glycols

Identity

PubMed Central ID

  • PMC8098754

Scopus Document Identifier

  • 85055890244

Digital Object Identifier (DOI)

  • 10.1016/j.ccell.2018.10.007

PubMed ID

  • 30423297

Additional Document Info

volume

  • 34

issue

  • 5